Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ATP4A | P20648 | 5/20 | 0.44 |
| ▸ | ATP4B | P51164 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135937 | 0.96 | ATP4A (0.49) | MAPTATP4AATP4BDRD2DRD3 | |
| SCHEMBL647665 | 0.95 | ATP4A (0.46) | ATP4AATP4BDRD2DRD3C5AR1 | |
| SCHEMBL5136749 | 0.94 | MAPT (0.48) | MAPTATP4AATP4BDRD2DRD3 | |
| SCHEMBL5144498 | 0.93 | BCHE (0.46) | MAPTATP4AATP4BDRD2DRD3 | |
| SCHEMBL5134950 | 0.93 | C5AR1 (0.45) | MAPTATP4AATP4BC5AR1 | |
| SCHEMBL5136633 | 0.92 | ATP4A (0.45) | ATP4AATP4BDRD2DRD3C5AR1 | |
| SCHEMBL5135329 | 0.92 | TP53 (0.46) | MAPTATP4AATP4BDRD2DRD3 | |
| SCHEMBL5073977 | 0.92 | ATP4A (0.46) | ATP4AATP4BDRD2DRD3C5AR1 | |
| SCHEMBL5135824 | 0.92 | C5AR1 (0.44) | MAPTATP4AATP4BC5AR1 | |
| SCHEMBL5136524 | 0.92 | C5AR1 (0.46) | MAPTC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |